Clinical Trial Update: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) [Phase 3]

View source ↗

Summary

Phase 3 trial update for donanemab (LY3002813) in early symptomatic Alzheimer's disease (TRAILBLAZER-ALZ 5) is active/not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• Donanemab (donanemab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer Disease, Dementia | Phase 3 | Status: ACTIVE_NOT_RECRUITING